What is Vidas Biomerieux?
VIDAS® is an automated, multiparametric immunoassay system. This uniquely designed testing device stores the calibration in the analyzer’s memory, thus optimizing the cost-per-sample result. This automated immunoassay system is reliable and economical.
What is Vidas in microbiology?
VIDAS® is a reliable and easy-to-use automated benchtop immunoanalyzer. Based on the Enzyme Linked Fluorescent Assay (ELFA) technology, it provides high quality on-demand test results.
What is immunoassay analyzer used for?
Immunoassay analyzers test patient samples for a variety of substances, including antiarrhythmic, antibiotic, anticonvulsant, or cardiac glycoside drug concentration determination; infectious diseases; allergy testing; cardiac markers; endocrine hormone testing; and protein, viral, or bacterial toxin determinations.
What is the role of Biomerieux in diagnostics?
Clinical diagnostics provide a critical role in the diagnosis and monitoring of numerous pathologies and infectious diseases. bioMérieux is your trusted partner in protecting product safety, with a broad range of high-quality, reliable products.
Which is the new generation of Vidas analyzer?
VIDAS 3 is the new-generation VIDAS analyzer, a brand trusted around the world in immunoassay testing for over two decades. Designed with your lab’s specific needs and workflow in mind, it is equipped with increased automation, traceability and connectivity for greater productivity.
Where can I get technical support for Biomerieux?
Please contact me with information about this product. If you would like technical support for your bioMérieux product, please call the Technical Support Center at 800-682-2666 (Clinical Customers) or 800-634-7656 (Industry Customers).
How is the vidas D-dimer exclusion II assay used?
Safe exclusion of Venous Thromboembolism. VIDAS ® D-Dimer Exclusion™ II is a highly-sensitive automated D-Dimer assay. In conjunction with assessment of clinical pretest probability, it allows safe exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE) in both low and intermediate suspected outpatient risk groups in just 20 minutes.